HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MoCRA Registration And Listing ‘Not A One And Done’; Start Thinking About Updates As Well

Executive Summary

Cosmetics manufacturers registering facilities with the US FDA should prepare for ongoing updates to registrations as they get new customers, manufacture new product types, or change manufacturing equipment, says Good Face Project, whose AI-powered software helps cosmetics companies design and launch competitive and compliant products.

You may also be interested in...

MoCRA Consultancy To Exempt Small Businesses: Tackle Product Listing While Stakes Are Low

Small businesses not required to register products with the FDA under new cosmetics regulations should consider doing so anyway in order to stay ahead of evolving requirements and complete work while ‘stakes are lower,’ said cosmetics software and consulting firm Good Face Project in a recent MoCRA webinar.

Information Deluge Headed US FDA’s Way When Cosmetics Registration Portal Opens

In comments on FDA draft guidance released in August, industry members raise questions about the agency’s capacity to deal with an anticipated flood of facility registrations and product listings. Confidentiality and international trade also figure among concerns.

CIR On MoCRA Product Listing: FDA Should Refine Categories For Optimal Data Collection

Cosmetic product/ingredient listing required by new cosmetics regulations will be a boon for CIR, which has conducted its ingredient reviews to date based on limited, voluntary data reporting. Adding new product classifications and subcategories to the US FDA’s listing system could provide needed insight into dry shampoo and other product formats and help identify potential for incidental inhalation risks.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts